HC Wainwright Boosts Sensus Healthcare (NASDAQ:SRTS) Price Target to $11.00

Sensus Healthcare (NASDAQ:SRTS) had its price target increased by analysts at HC Wainwright from $10.00 to $11.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 31.50% from the stock’s current price. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.11 EPS, FY2024 earnings at $0.42 EPS, Q1 2025 earnings at $0.14 EPS, Q2 2025 earnings at $0.10 EPS and FY2025 earnings at $0.52 EPS.

Separately, Maxim Group increased their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th.

Sensus Healthcare Stock Down 0.5 %

NASDAQ:SRTS opened at $8.37 on Monday. The company has a market cap of $137.10 million, a P/E ratio of 14.75 and a beta of 1.04. The firm’s 50 day moving average is $6.42 and its two-hundred day moving average is $6.00. Sensus Healthcare has a fifty-two week low of $2.02 and a fifty-two week high of $8.69.

Institutional Trading of Sensus Healthcare

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Truvestments Capital LLC purchased a new stake in Sensus Healthcare during the third quarter worth approximately $32,000. Chapin Davis Inc. purchased a new stake in Sensus Healthcare during the 2nd quarter worth $53,000. Geode Capital Management LLC increased its holdings in Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after purchasing an additional 11,525 shares in the last quarter. Sachetta LLC increased its holdings in Sensus Healthcare by 12.9% in the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company’s stock valued at $631,000 after purchasing an additional 13,544 shares in the last quarter. Finally, XTX Topco Ltd raised its position in Sensus Healthcare by 76.0% in the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after purchasing an additional 13,619 shares during the period. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.